Filing Flows › Ionis Pharmaceuticals (IONS) › Guidance & outlook
Ionis Pharmaceuticals (IONS) guidance and outlook
Ionis Pharmaceuticals' 10-Q filed Nov 9, 2026 makes 7 forward-looking statements.
Guidance and outlook
Forward-looking statements, 10-Q filed Nov 9, 2026
- As a pioneer in RNA-targeted medicines with a deep understanding of disease biology and an industry-leading drug discovery technology, we are driven to deliver innovative, life-changing advances for patients.
- Our key recent achievements, combined with our independent and partnered product launches anticipated by the end of 2027, position us well to help millions of patients with serious diseases and deliver increasing product and royalty revenue.
- ● Assessing the appropriate estimate of anticipated future royalty payments under our royalty purchase agreement
- We expect our operating expenses, excluding non-cash compensation expense related to equity awards, to continue to increase during the remainder of 2026 as we advance our commercialization activities.
- We use our proprietary technologies to generate information about the function of genes and to determine the value of genes as drug discovery targets.
- We expect SG&A expenses to increase as we continue to invest in our independent commercial launches.
- We currently intend to use our cash, cash equivalents and short-term investments to finance our activities.
Ionis Pharmaceuticals' latest quarter
Ionis Pharmaceuticals, Q3 2026: revenue $243M (+55% year over year), operating margin -53.8%, net loss $110M, operating cash flow −$179M. The chart follows the revenue to costs, profit and cash.
Questions
What does Ionis Pharmaceuticals expect?
As a pioneer in RNA-targeted medicines with a deep understanding of disease biology and an industry-leading drug discovery technology, we are driven to deliver innovative, life-changing advances for patients. Our key recent achievements, combined with our independent and partnered product launches anticipated by the end of 2027, position us well to help millions of patients with serious diseases and deliver increasing product and royalty revenue. ● Assessing the appropriate estimate of anticipated future royalty payments under our royalty purchase agreement
Updated Nov 9, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.